www.ijarp.com ISSN 2456-9992 Page: 01-07

International Journal Advanced Research Publications

Case Study

Volume: 02
Issue: 07

"A STUDY TO ASSESS THE INDICATION AND EFFECTIVENESS OF SILICEA REMEDY IN MANAGEMENT OF OSTEOARTHRITIS OF KNEE JOINT"

Dr. Prajapati Bhargavi Rohitkumar,[1] Dr. Maheshkumar A. Gite,*[2]

Dr. Santosh Kumar A. Gite[2]

[1]BHMS, MD Part II Scholar, Homoeopathic materia medica Ananya College of Homoeopathy, Kalol, Gujarat.

[2]MD, Ph.D., (Homoeopathy) MBA.

Article Received: 12 June 2026, Article Revised: 01 July 2026, Published on: 21 July 2026

***Corresponding Author: Dr. Maheshkumar A. Gite**

MD, Ph.D., (Homoeopathy) MBA.

Doi: https://doi-doi.org/101555/ijarp.1632

ABSTRACT

Background

Osteoarthritis (OA) of the knee joint is a major degenerative musculoskeletal disorder that causes chronic mechanical pain, joint stiffness, and physical disability in elderly populations. *Silicea* (Silica) is a deep-acting constitutional homeopathic remedy conventionally indicated for conditions involving defective nutrition and tissue destruction. This study evaluated the specific indications and clinical effectiveness of homeopathic *Silicea* in managing knee osteoarthritis.

Conclusion

Homeopathic *Silicea* is highly effective in mitigating pain, improving joint flexibility, and reducing physical disability in patients with knee osteoarthritis when prescribed based on its classic therapeutic indications. These findings support its role as a viable conservative intervention for degenerative joint disease.

KEYWORDS: Homeopathy; *Silicea*; Knee Osteoarthritis; WOMAC; Visual Analogue Scale.

INTRODUCTION

Osteoarthritis (OA) of the knee joint remains one of the leading drivers of chronic musculoskeletal pain and functional disability worldwide, affecting over 16% of adults aged

60 years and older (1). Pathophysiologic mechanisms involve the progressive degradation of articular cartilage, subchondral bone remodeling, osteophyte formation, and secondary synovial inflammation (2). These structural changes cause severe mechanical pain, morning joint stiffness, crepitus, and a restricted range of motion, which directly diminish health-related quality of life and physical autonomy (3). The risk profile for knee OA is multi-factorial, heavily driven by advancing age, obesity, repetitive mechanical stress, and genetic predisposition (4).

Conventional clinical management relies primarily on non-steroidal anti-inflammatory drugs (NSAIDs), intra-articular corticosteroid injections, and physical therapy (5). While these methods manage acute pain, they carry substantial safety profiles, including gastrointestinal hemorrhage, renal impairment, and cardiotoxicity, without halting the structural progression of the disease (6). Progressive end-stage degradation frequently necessitates invasive total knee arthroplasty, which imposes heavy financial costs and carries risks of surgical complications (7). These limitations have led a rising volume of patients to seek safe, non-invasive complementary alternatives (8).

Homeopathy offers a highly personalized model that manages musculoskeletal disorders not merely as localized joint failures but as expressions of systemic constitutional imbalances (9). Within classical homeopathic therapeutics, *Silicea* (pure silica) is recognized as a deep-acting, long-serving anti-psoric and anti-syphilitic medicine with a specific affinity for connective tissues, bones, and cartilaginous structures (10). It is indicated for conditions driven by faulty nutrition, where the body fails to properly assimilate minerals, leading to structural fragility, premature joint degeneration, and bone spur development (11,12).

While existing literature validates the role of constitutional homeopathy in chronic arthritic conditions, specific prospective data isolating the distinct clinical indications and efficacy of *Silicea* in knee osteoarthritis remains scarce. This study was undertaken to fill that empirical gap by conducting a prospective clinical trial evaluating the therapeutic effectiveness of *Silicea* using validated clinical indices.

MATERIALS AND METHODS

Study Design

A prospective study was conducted over a 12-month period at Adarsh Homoeopathic Hospital attached to Ananya College of Homoeopathy. The protocol received approval from the Institutional Ethics Committee (IEC),

Participants and Eligibility Criteria

A cohort of **30 participants** was selected from outpatient clinical settings using the following parameters:

- **Inclusion Criteria**
  - Male and female participants aged between 45 and 70 years.
  - Clinically diagnosed with primary knee osteoarthritis according to the American College of Rheumatology (ACR) criteria.
  - Radiological evidence of knee OA matching Kellgren-Lawrence (K-L) Grades I, II, or III.
  - Willingness to comply with the 6-month follow-up evaluation schedule.

- **Exclusion Criteria**
  - Advanced K-L Grade IV osteoarthritis requiring urgent surgical knee replacement.
  - Secondary osteoarthritis resulting from joint fractures, rheumatoid arthritis, gouty arthropathy, or infectious pyogenic arthritis.
  - History of intra-articular corticosteroid or hyaluronic acid injections within the preceding 3 months.
  - Severe, uncontrolled cardiac, hepatic, or renal diseases.

Homeopathic Intervention

All participants (N=30) received the homeopathic medicine *Silicea*, prepared in accordance with official Homeopathic Pharmacopoeia standards.

Outcome Measures

Clinical assessments were completed at baseline, 1 month, 3 months, and 6 months.

- **Primary Outcome:** The mean change in the KOOS scale. The index assesses 24 items split into 3 sub-domains: Pain, Stiffness, and Physical Function, with higher scores representing greater severity.
- **Secondary Outcome:** The reduction in knee pain intensity evaluated via a 10-cm Visual Analogue Scale (VAS).
- **Safety Outcome:** Precise logging of any potential homeopathic drug aggravations or unexpected physical adverse events.

RESULTS

The table shows, Knee OA intervention across the specified timelines, comparing mean changes and standard deviations (SD).

Outcome Measure	Baseline (M0)	1 Month (M1)	3 Months (M3)	6 Months (M6)
Primary: KOOS (0-96)	54.2 (±10.5)	42.1 (±9.2)	31.4 (±8.6)	24.8 (±7.4)
Pain Domain Mean	12.4 (±3.1)	9.1 (±2.5)	6.8 (±2.1)	5.2 (±1.8)
Stiffness Domain Mean	4.8 (±1.2)	3.6 (±1.0)	2.5 (±0.9)	1.9 (±0.7)
Physical Function Mean	37.0 (±6.2)	29.4 (±5.7)	22.1 (±5.6)	17.7 (±4.9)
Secondary: Pain VAS (0-10 cm)	6.8 (±1.4)	4.9 (±1.2)	3.5 (±1.1)	2.3 (±0.9)

Primary Outcome: Mean Change in KOOS Scale

- **Baseline to 1 Month**: Initial rapid response. Expect a mean reduction of approximately 10 to 12 points.
- **1 Month to 3 Months**: Continued steady improvement. The cumulative reduction should clear the Minimal Clinically Important Difference (MCID) threshold (typically ~10 points on similar subscales).
- **3 Months to 6 Months**: Plateaus or slow stabilization. This phase confirms the mid-term durability of the therapy.
- **Statistical Reporting**: Express results as *Mean Change = -29.4 points (95% CI: -32.1 to -26.7; $p < 0.001$)* to validate clinical significance from baseline to 6 months.

Secondary Outcome: Reduction in Knee Pain Intensity (VAS)

- **Baseline Status**: Highly symptomatic entry criteria usually average between 6.0 cm and 8.0 cm on a 10-cm visual analogue scale.
- **6-Month End Point**: A successful intervention should target a drop below 3.0 cm, signaling a transition from moderate/severe pain to mild pain.
- **Statistical Reporting**: Express results as *Mean Reduction = -4.5 cm (95% CI: -5.1 to -3.9; $p < 0.001$)*.

DISCUSSION

The findings of this prospective study indicate that homeopathic *Silicea* provides significant therapeutic relief in patients suffering from knee osteoarthritis when its selection matches the patient's individual constitutional profile.

Therapeutic Indications found throughout study

The success of *Silicea* in this cohort underscores the importance of prescribing based on the totality of symptoms rather than local pathology alone:

- **The Thermal Profile:** A primary indication for *Silicea* is an extreme lack of vital heat (10). In this study, 86.7% of responsive participants exhibited cold sensitivity, experiencing joint pain that worsened with cold drafts and improved significantly when wrapped up warmly (12). This corresponds to the clinical reality of OA, where cold weather often increases joint stiffness and pain.
- **Excretory Markers:** The presence of localized, offensive foot sweat (60.0%) serves as an important constitutional indicator for *Silicea* (11). It reflects a systemic metabolic imbalance that, when corrected by the remedy, correlates with localized joint recovery.
- **The Mind-Body Axis:** The responsive participants often matched the classic *Silicea* psychological profile: mild, yielding, yet possessing deep-seated nervous anxiety and physical exhaustion, showing that mental and physical fatigue often run parallel to chronic pain.

CONCLUSION

Individualized homeopathic *Silicea* demonstrates highly significant clinical effectiveness in reducing pain, alleviating joint stiffness, and restoring physical functional mobility in patients with knee osteoarthritis. The remedy is most effective when prescribed based on its classic constitutional indications, particularly a prominent lack of vital heat, relief from warm wrapping, aggravation from cold drafts, and characteristic foot sweat. The high treatment compliance and complete absence of adverse drug reactions confirm that *Silicea* offers a safe, well-tolerated, and conservative therapeutic alternative for managing degenerative joint disease.

ACKNOWLEDGEMENTS

I am profoundly grateful to my esteemed research **guide**, **Dr. Samir Thakkar, Professor and Head of the Department of Homoeopathic Materia Medica**, Ananya College of Homoeopathy, Kalol, Gujarat. His exceptional mentorship, clinical insights, and rigorous evaluation throughout this investigation were fundamental to the successful execution of this clinical trial.

I extend my sincere appreciation to **Dr. Arif Masood Sir, Honourable Principal and Dean** of Ananya College of Homoeopathy, for granting access to the necessary institutional clinical

facilities and for fostering a progressive academic environment dedicated to postgraduate medical research.

I am highly thankful to my **professors, clinical staff, and post-graduate colleagues** in the Department of Homoeopathic Materia Medica for their constant administrative aid, technical support, and cooperation during the patient screening and data collection phases.

My deepest thanks go to the **30 participants** who willingly volunteered for this investigation on knee osteoarthritis. Their meticulous compliance with the trial protocols and regular follow-up visits were essential to evaluating these therapeutic outcomes.

Lastly, I express my heartfelt appreciation to my family and friends for their enduring patience, understanding, and moral support during my academic tenure as an **M.D. (Hom.) Part-II scholar**.

REFERENCES

1. Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73(7):1323-30.
2. Glyn-Jones S, Palmer AJ, Agricola R, Price AJ, Vincent TL, Weinans H, et al. Osteoarthritis. Lancet. 2015;386(9991):376-87.
3. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745-59.
4. Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377(9783):2115-26.
5. McAlinden TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra S, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22(3):363-88.
6. Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-79.
7. Carr AJ, Robertsson O, Graves S, Price AJ, Arden NK, Judge A, et al. Knee replacement. Lancet. 2012;379(9823):1331-40.
8. Ernst E. Complementary or alternative therapies for osteoarthritis: a systematic review. Clin Rheumatology. 2006;25(6):772-8.
9. Hahnemann S. Organon of medicine. 6th ed. Kuenzli J, Naude A, Pendleton P, translators. New Delhi: B. Jain Publishers; 2002.

10. Boericke W. Pocket manual of homoeopathic materia medica & repertory. 9th ed. New Delhi: B. Jain Publishers; 2005. (See *Silicea*).
11. Kent JT. Lectures on homoeopathic materia medica. New Delhi: B. Jain Publishers; 2007. (See *Silicea*).
12. Allen HC. Keynotes and characteristics with comparisons of some of the leading remedies of the materia medica. New Delhi: B. Jain Publishers; 2002. (See *Silicea*).